Please find attached Audited Financial Results for the quarter and year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Veerhealth Care's FY25 revenue from operations rose to Rs 1,667.05 lakhs from Rs 1,322.31 lakhs in FY24, a growth of about 26%. Full-year profit after tax was broadly flat at Rs 39.14 lakhs versus Rs 40.60 lakhs last year. The fourth quarter (Q4 FY25) ended with a small loss of Rs 9.93 lakhs at the PAT level, though this was an improvement over the Rs 55.37 lakh loss in Q4 FY24. EBITDA margins clearly compressed, with operating profit before depreciation and finance costs falling from Rs 200.21 lakhs (about 13.7% margin) in FY24 to Rs 167.95 lakhs (about 9.4% margin) in FY25. Cash flow from operations turned negative at Rs -39.32 lakhs (against Rs 289.58 lakhs in FY24), mainly due to higher inventory and other working capital movements. The company also raised new borrowings of Rs 419.90 lakhs (long-term) and Rs 70.91 lakhs (short-term), against zero borrowings a year earlier, and used Rs 880.91 lakhs for purchase of property, plant and equipment. The board has not recommended any dividend, and the auditor issued an unmodified opinion.
Strong top-line growth is a positive, but shrinking margins, negative operating cash flow, and fresh debt taken on for capex may worry investors about profitability and cash quality. Shareholders should expect no dividend income for FY25 and watch how the new borrowing-funded expansion translates into future earnings.